Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Basic fibroblast growth factor (bFGF) + gelatin sponge + fibrin glue is a combination therapy used primarily for tissue regeneration and wound healing applications. This combination creates a delivery system where: 1. Basic fibroblast growth factor (bFGF) serves as the active biological component that stimulates cell proliferation, migration, differentiation, and angiogenesis[1][3]. 2. Gelatin sponge functions as a biodegradable scaffold that provides structural support and controlled release of bFGF. 3. Fibrin glue acts as an adhesive agent that helps secure the delivery system to the target tissue while also contributing to the slow release of bFGF[4]. This combination addresses the challenge of bFGF's short half-life and rapid degradation in vivo by creating a sustained-release delivery system that maintains the biological activity of bFGF at the target site[1]. The mixture has been studied for applications in tissue repair and regeneration, particularly in neural tissue, where it has shown promise in reducing cerebral infarction and promoting recovery after injury[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on basic fibroblast growth factor + gelatin sponge + fibrin glue.